Abeona Therapeutics Inc
NASDAQ:ABEO

  • LAST PRICE
    5.9800
  • TODAY'S CHANGE (%)
    0.1900 (3.2815%)
  • Bid / Lots
    5.9100/ 13
  • Ask / Lots
    6.1300/ 2
  • Open / Previous Close
    5.8000 / 5.7900
  • Day Range
    5.7600
    6.1700
  • 52 Week Range
    3.0500
    9.0100
  • Volume
    387,598

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

      Show headlines and story abstract

    • 7:33AM ET on Thursday Nov 14, 2024 by MT Newswires
      Companies Mentioned: ABEO
      07:33 AM EST, 11/14/2024 (MT Newswires) -- ...

    • 7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: ABEO

      (Unaudited)
      For the three months ended For the nine months ended September 30, September 30, -------------------------- ---------------------------- 2024 2023 2024 2023 Revenues: License and other revenues $ -- $ -- $ -- $ 3,500 Expenses: Royalties -- 30 -- 1,605 Research and development 8,941 7,148 25,366 23,712 General and administrative 6,404 4,156 22,173 13,174 Gain on operating lease right-of-use assets -- -- -- (1,065) Total expenses 15,345 11,334 47,539 37,426 ---------- ---------- ---------- ---------- Loss from operations (15,345) (11,334) (47,539) (33,926) Interest income 1,189 593 3,223 1,374 Interest expense (1,102) (105) (3,126) (309) Change in fair value of warrant and derivative liabilities (15,156) (1,101) (7,530) (7,465) Other income 145 111 531 2,729 Net Loss $ (30,269) $ (11,836) $ (54,441) $ (37,597) ========== ========== ========== ========== Basic and diluted loss per common share $ (0.63) $ (0.48) $ (1.41) $ (1.89) ========== ========== ========== ========== Weighted average number of common shares outstanding - basic and diluted 48,081,758 24,797,564 38,504,273 19,942,613 ========== ========== ========== ========== Other comprehensive income (loss): Change in unrealized gains (losses) related to available-for-sale debt securities 50 (33) (18) 1 Foreign currency translation adjustments -- 29 -- 29 Comprehensive loss $ (30,219) $ (11,840) $ (54,459) $ (37,567) ========== ========== ========== ==========

    • 7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: ABEO

      (Unaudited)
      For the three months ended For the nine months ended September 30, September 30, -------------------------- ---------------------------- 2024 2023 2024 2023 Revenues: License and other revenues $ -- $ -- $ -- $ 3,500 Expenses: Royalties -- 30 -- 1,605 Research and development 8,941 7,148 25,366 23,712 General and administrative 6,404 4,156 22,173 13,174 Gain on operating lease right-of-use assets -- -- -- (1,065) Total expenses 15,345 11,334 47,539 37,426 ---------- ---------- ---------- ---------- Loss from operations (15,345) (11,334) (47,539) (33,926) Interest income 1,189 593 3,223 1,374 Interest expense (1,102) (105) (3,126) (309) Change in fair value of warrant and derivative liabilities (15,156) (1,101) (7,530) (7,465) Other income 145 111 531 2,729 Net Loss $ (30,269) $ (11,836) $ (54,441) $ (37,597) ========== ========== ========== ========== Basic and diluted loss per common share $ (0.63) $ (0.48) $ (1.41) $ (1.89) ========== ========== ========== ========== Weighted average number of common shares outstanding - basic and diluted 48,081,758 24,797,564 38,504,273 19,942,613 ========== ========== ========== ========== Other comprehensive income (loss): Change in unrealized gains (losses) related to available-for-sale debt securities 50 (33) (18) 1 Foreign currency translation adjustments -- 29 -- 29 Comprehensive loss $ (30,219) $ (11,840) $ (54,459) $ (37,567) ========== ========== ========== ==========

  • Nov 12, 2024

  • Nov 4, 2024

Peers Headlines